deltatrials
Terminated PHASE2 INTERVENTIONAL 2-arm NCT02950025

Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

A Randomized Controlled Phase II Study of Daily Online Adaptation Versus Localization for MRI-Guided SBRT for Unresectable Primary or Oligometastatic Abdominal Malignancies

Sponsor: Washington University School of Medicine

Conditions Cancer of the Pancreas Hepatocellular Carcinoma Pancreas Cancer Pancreatic Cancer
Interventions European Organization for Research and Treatment of Cancer (EORTC) QLQ-30 Online, adaptive MR-guided SBRT Online, non-adaptive MR-guided SBRT
Updated 15 times since 2017 Last updated: Mar 26, 2019 Started: Jan 19, 2017 Primary completion: Mar 19, 2018 Completion: Mar 19, 2018
This information is for research purposes only and is not medical advice. Consult a healthcare provider before making any medical decision.

Terminated

Low accrual

Other terminated trials from Washington University School of Medicine

See all terminations from Washington University School of Medicine

Listed as NCT02950025, this PHASE2 trial focuses on Cancer of the Pancreas and Hepatocellular Carcinoma and remains terminated or withdrawn. Sponsored by Washington University School of Medicine, it has been updated 15 times since 2017, reflecting substantial change activity. This study contributes to the evolving evidence base for cancer treatment protocols.

Status Flow

~Jan 2017 – ~Feb 2017 · 31 days · monthly snapshot~Feb 2017 – ~Feb 2018 · 12 months · monthly snapshot~Feb 2018 – ~Jun 2018 · 4 months · monthly snapshot~Jun 2018 – ~Sep 2018 · 3 months · monthly snapshot~Sep 2018 – ~Apr 2019 · 7 months · monthly snapshot~Apr 2019 – ~May 2019 · 30 days · monthly snapshot~May 2019 – ~Feb 2020 · 9 months · monthly snapshot~Feb 2020 – ~Jan 2021 · 11 months · monthly snapshot~Jan 2021 – ~Dec 2021 · 11 months · monthly snapshot~Dec 2021 – ~Dec 2022 · 12 months · monthly snapshot~Dec 2022 – ~Jan 2023 · 31 days · monthly snapshot~Jan 2023 – ~Jul 2024 · 18 months · monthly snapshot~Jul 2024 – ~Sep 2024 · 2 months · monthly snapshot~Sep 2024 – ~Sep 2025 · 12 months · monthly snapshot~Sep 2025 – present · 11 months · monthly snapshot

Change History

15 versions recorded

  1. Sep 2025 — Present [monthly]

    Terminated PHASE2

  2. Sep 2024 — Sep 2025 [monthly]

    Terminated PHASE2

  3. Jul 2024 — Sep 2024 [monthly]

    Terminated PHASE2

  4. Jan 2023 — Jul 2024 [monthly]

    Terminated PHASE2

  5. Dec 2022 — Jan 2023 [monthly]

    Terminated PHASE2

▶ Show 10 earlier versions

  1. Dec 2021 — Dec 2022 [monthly]

    Terminated PHASE2

  2. Jan 2021 — Dec 2021 [monthly]

    Terminated PHASE2

  3. Feb 2020 — Jan 2021 [monthly]

    Terminated PHASE2

  4. May 2019 — Feb 2020 [monthly]

    Terminated PHASE2

  5. Apr 2019 — May 2019 [monthly]

    Terminated PHASE2

  6. Sep 2018 — Apr 2019 [monthly]

    Terminated PHASE2

    Status: Recruiting → Terminated

  7. Jun 2018 — Sep 2018 [monthly]

    Recruiting PHASE2

  8. Feb 2018 — Jun 2018 [monthly]

    Recruiting PHASE2

  9. Feb 2017 — Feb 2018 [monthly]

    Recruiting PHASE2

    Status: Not Yet Recruiting → Recruiting

  10. Jan 2017 — Feb 2017 [monthly]

    Not Yet Recruiting PHASE2

    First recorded

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:
  • Washington University School of Medicine
Data source: Washington University School of Medicine

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations